Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Public ClinicalTrials.gov record NCT04665739. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Lutetium Lu 177-dotate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Lutetium Lu 177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors.
Study identification
- NCT ID
- NCT04665739
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 70 participants
Conditions and interventions
Conditions
- Advanced Lung Neuroendocrine Tumor
- Functioning Lung Neuroendocrine Tumor
- Locally Advanced Lung Neuroendocrine Neoplasm
- Lung Neuroendocrine Neoplasm
- Lung Neuroendocrine Tumor G1
- Lung Neuroendocrine Tumor G2
- Metastatic Lung Neuroendocrine Neoplasm
- Metastatic Lung Neuroendocrine Tumor
- Non-Functioning Lung Neuroendocrine Tumor
- Recurrent Lung Neuroendocrine Neoplasm
- Unresectable Lung Neuroendocrine Neoplasm
- Unresectable Lung Neuroendocrine Tumor
Interventions
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Everolimus Drug
- Fludeoxyglucose F-18 Other
- Lutetium Lu 177 Dotatate Drug
- Magnetic Resonance Imaging Procedure
- Positron Emission Tomography Procedure
- Single Photon Emission Computed Tomography Procedure
- Survey Administration Other
Procedure · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 3, 2023 (Actual)
- Primary completion
- Jul 1, 2027 (Estimated)
- Completion
- Jul 1, 2027 (Estimated)
- Last update posted
- Oct 14, 2026
2023 – 2027
United States locations
- U.S. sites
- 29
- U.S. states
- 14
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Cancer Center | Birmingham | Alabama | 35233 | Withdrawn |
| Tower Cancer Research Foundation | Beverly Hills | California | 90211 | Recruiting |
| Loma Linda University Medical Center | Loma Linda | California | 92354 | Suspended |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | Recruiting |
| UCSF Medical Center-Mission Bay | San Francisco | California | 94158 | Recruiting |
| Torrance Memorial Physician Network - Cancer Care | Torrance | California | 90505 | Recruiting |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | Suspended |
| UM Sylvester Comprehensive Cancer Center at Aventura | Aventura | Florida | 33180 | Suspended |
| UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables | Florida | 33146 | Recruiting |
| UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach | Florida | 33442 | Recruiting |
| University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami | Florida | 33136 | Recruiting |
| UM Sylvester Comprehensive Cancer Center at Plantation | Plantation | Florida | 33324 | Recruiting |
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | Recruiting |
| UC Comprehensive Cancer Center at Silver Cross | New Lenox | Illinois | 60451 | Recruiting |
| University of Chicago Medicine-Orland Park | Orland Park | Illinois | 60462 | Recruiting |
| UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny | Iowa | 50023 | Recruiting |
| Iowa Methodist Medical Center | Des Moines | Iowa | 50309 | Recruiting |
| UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines | Iowa | 50309 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Recruiting |
| Missouri Baptist Medical Center | St Louis | Missouri | 63131 | Recruiting |
| Duke University Medical Center | Durham | North Carolina | 27710 | Suspended |
| Case Western Reserve University | Cleveland | Ohio | 44106 | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Recruiting |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | Recruiting |
| Temple University Hospital | Philadelphia | Pennsylvania | 19140 | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| Vanderbilt University/Ingram Cancer Center | Nashville | Tennessee | 37232 | Suspended |
| Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah | 84112 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04665739, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04665739 live on ClinicalTrials.gov.